血糖70至139 mg/dL范围内时间百分比与接受静脉胰岛素治疗的危重患者死亡率降低相关
该研究多中心回顾性分析9,028例接受同一静脉胰岛素方案的危重患者,计算血糖70至139 mg/dL范围内时间百分比(TIR),并以既往3个月内或入院后1个月内最高糖化血红蛋白值作为既往血糖控制的替代指标。结果显示,非糖尿病患者中位TIR为84.1%,糖尿病患者为64.5%;TIR>80%者死亡率12.4%,低于TIR≤80%者的19.2%(P<.001)。分层回归分析中,TIR>80%与非糖尿病患者(OR 0.52,P<.001)、糖尿病患者(OR 0.69,P=.001)及既往血糖控制良好者(OR 0.50,P<.001)的死亡率降低独立相关,但在既往血糖控制不佳者中未达统计学显著(OR 0.86,P=.40)。
要点
- 多中心回顾性分析9,028例接受同一静脉胰岛素方案的危重患者,TIR>80%者30天死亡率12.4%,低于TIR≤80%者的19.2%(P<.001)。
- 非糖尿病患者中位TIR为84.1%,糖尿病患者为64.5%。
- TIR>80%与非糖尿病患者死亡率降低独立相关(OR 0.52,P<.001),与糖尿病患者死亡率降低独立相关(OR 0.69,P=.001)。
- TIR>80%与既往血糖控制良好者死亡率降低独立相关(OR 0.50,P<.001),但在既往血糖控制不佳者中未达统计学显著(OR 0.86,P=.40)。
- 研究排除糖尿病酮症酸中毒、血糖读数<10次及重复入院患者,以既往3个月内或入院后1个月内最高糖化血红蛋白值作为既往血糖控制替代指标。
适用人群与场景
- 接受同一静脉胰岛素方案治疗的多中心危重患者。
- 排除糖尿病酮症酸中毒患者、血糖读数<10次的患者及重复入院患者。
诊断标准与关键阈值
- 目标血糖范围定义为70至139 mg/dL,计算该范围内时间百分比(TIR)。
- 以TIR>80%作为分层阈值。
- 以既往3个月内或入院后1个月内最高糖化血红蛋白值作为既往血糖控制的替代指标。
研究设计与关键结果
- 研究类型为多中心回顾性分析,共纳入9,028例接受同一静脉胰岛素方案的危重患者,其中53.2%患有糖尿病。
- 非糖尿病患者中位TIR为84.1%,糖尿病患者中位TIR为64.5%。
- TIR>80%者30天死亡率为12.4%,TIR≤80%者为19.2%(P<.001)。
- 分层回归分析显示,TIR>80%与非糖尿病患者死亡率降低独立相关(OR 0.52,P<.001),与糖尿病患者死亡率降低独立相关(OR 0.69,P=.001),与既往血糖控制良好者死亡率降低独立相关(OR 0.50,P<.001),但在既往血糖控制不佳者中未达统计学显著(OR 0.86,P=.40)。
证据类型、等级与局限
- 证据类型:多中心回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在接受静脉胰岛素治疗的危重患者中,血糖70至139 mg/dL范围内时间百分比(TIR)>80%与30天死亡率降低独立相关,尤其见于既往血糖控制良好者;在既往血糖控制不佳者中该关联未达统计学显著。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In addition to hyperglycemia, hypoglycemia, and glycemic variability, reduced time in targeted blood glucose range (TIR) is associated with increased risk of death in critically ill patients. This relation between TIR and mortality may be confounded by diabetic status and antecedent glycemic control.
METHODS: This study retrospectively analyzed critically ill patients managed with the same IV insulin protocol at multiple centers. The percentage of TIR between 70 and 139 mg/dL was calculated. Patients with diabetic ketoacidosis, patients who had < 10 blood glucose readings, and patients with repeat admissions were excluded. The highest recorded glycosylated hemoglobin value in the preceding 3 months or up to 1 month following admission were used as a surrogate for the patient's preexisting glucose control. Stratified regression analyses were performed for 30-day mortality, with covariates of age, sex, TIR ≥ 80%, Acute Physiology Score, and Charlson Comorbidity Index.
RESULTS: A total of 9,028 patients, 53.2% of whom had diabetes, were studied. Median TIR was 84.1% for nondiabetic patients and 64.5% for patients with diabetes. Mortality was lower in those with TIR > 80% compared with those with TIR ≤ 80% (12.4% vs 19.2%; P < .001). TIR > 80% was independently associated with reduced mortality in nondiabetic patients (OR, 0.52; P < .001), patients with diabetes (OR, 0.69; P = .001), and patients with well-controlled disease (OR, 0.50; P < .001) but not in patients with poorly controlled disease (OR, 0.86; P = .40).
CONCLUSIONS: TIR was independently associated with mortality in critically ill patients, particularly those with good antecedent glucose control.
参考来源
- Lanspa MJ, Krinsley JS, Hersh AM, et al. Percentage of Time in Range 70 to 139 mg/dL Is Associated With Reduced Mortality Among Critically Ill Patients Receiving IV Insulin Infusion. Chest. 2019. PMID: 31201784. doi:10.1016/j.chest.2019.05.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。